The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of afatinib plus chemotherapy with genomic profiling in osimertinib-refractory EGFR-mutant NSCLC: NEJ025B.
 
Akihiko Miyanaga
Honoraria - AstraZeneca; Nippon Kayaku; Novartis; Ono Pharmaceutical; Takeda
 
Hiromi Nagashima
No Relationships to Disclose
 
Yu Utsumi
No Relationships to Disclose
 
Tatsuro Fukuhara
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Lilly Japan (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)
 
Aya Suzuki
No Relationships to Disclose
 
Masahiro Seike
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo Company; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Nippon Kayaku; Taiho Pharmaceutical
 
Koichi Azuma
Honoraria - Amgen (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/UCB Japan (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); MSD Oncology (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst)
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Akira Kisohara
No Relationships to Disclose
 
Jun Sugisaka
Honoraria - AstraZeneca; Kyowa Kirin International
 
Hajime Asahina
Honoraria - AstraZeneca Canada; BMS Brazil; Chugai Foundation for Innovative Drug Discovery Science; Lilly; MSD; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca Canada
Research Funding - AstraZeneca
 
Hisashi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Ryota Kanemaru
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst)
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo KK; Merck; Ono Pharmaceutical
 
Naoki Furuya
No Relationships to Disclose
 
Haruna Sato
No Relationships to Disclose
 
Kazuhisa Nakashima
No Relationships to Disclose
 
Kazuko Sakai
No Relationships to Disclose
 
Kazuto Nishio
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Guardant Health; Janssen; Lilly Japan; Maruho; MSD K.K.; Nichirei; Novartis; SymBio Pharmaceuticals
Research Funding - Hitachi Chemical; Japan Breast Cancer Research Group; Lilly Japan; Okayama University; Osaka Minami Hospital; Otsuka; Thoracic Oncology Research Group; University Public Corporation Osaka.; West Japan Oncology Group
 
Fumiaki Takahashi
No Relationships to Disclose
 
Makoto Maemondo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo; Lilly; Merck Sharp and Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Boehringer Ingelheim (Inst); Chugai Pharma; Janssen (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)